Isoleucine thiazolidide - Vivoryon Therapeutics
Alternative Names: P-32-98; P32/98Latest Information Update: 17 Jun 2019
Price :
$50 *
At a glance
- Originator Probiodrug
- Developer Vivoryon Therapeutics
- Class Antihyperglycaemics; Small molecules; Thiazolidines
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 11 Jun 2019 Probiodrug is now called Vivoryon Therapeutics
- 04 Dec 2002 Probiodrug has granted a non-exclusive licence to Ferring and its sublicensee, Ortho-McNeil Pharmaceuticals, for the inhibitors if dipeptidyl peptidase IV for diabetes and obesity
- 06 Apr 2001 Phase-II clinical trials for Type-2 diabetes mellitus in Germany (PO)